Potential of GLP-1 Analogs in Managing Hyperphagia and Obesity in Prader-Willi Syndrome: A Review of Efficacy and Safety
DOI:
https://doi.org/10.12775/QS.2024.25.54915Keywords
Prader Willi Syndrome, obesity, hyperphagia, GLP agonist, GLP-1RAAbstract
Introduction: Prader-Willi Syndrome (PWS) is a genetic disorder marked by hyperphagia, obesity, developmental delays, and behavioral challenges. Traditional treatments like dietary control and growth hormone therapy often fail to effectively manage these symptoms. Recently, glucagon-like peptide-1 (GLP-1) analogs have shown potential in treating PWS. This review assesses the efficacy, safety and mechanisms of GLP-1 analogs in PWS treatment. They improve glycemic control, cardiovascular health, and appetite regulation, contributing to better weight management and overall health in PWS patients. These analogs enhance insulin secretion, inhibit glucagon release, and slow gastric emptying, helping to reduce postprandial glucose spikes and caloric intake.
Results: Several small-scale studies and case reports have shown mixed results regarding the effectiveness of GLP-1 analogs in reducing BMI and hyperphagia in PWS patients. Although the studies demonstrated varied outcomes in terms of BMI reduction, all of them reported improvement in satiety or appetite levels.
Conclusions: Overall, GLP-1 analogs hold promise for addressing hyperphagia, obesity, and glycemic control in PWS patients, improving their overall health and quality of life. Continued research and long-term studies are essential to establish these benefits and optimize treatment strategies.
References
Suzanne B. Cassidy, Stuart Schwartz , Jennifer L. Miller, Daniel J. Driscoll. Prader-Willi syndrome. Genetics in Medicine. 2012;14(1):10-26. https://doi.org/10.1038/gim.0b013e31822bead0
Butler MG, Miller JL, Forster JL. Prader-Willi Syndrome - Clinical Genetics, Diagnosis and Treatment Approaches: An Update. Curr Pediatr Rev. 2019;15(4):207-244. https://doi.org/10.2174/1573396315666190716120925
Diene, G., Mimoun, E., Feigerlova, E., Caula, S., Molinas, C., Grandjean, H., Tauber, M., & French Reference Centre for PWS. Endocrine disorders in children with Prader-Willi syndrome--data from 142 children of the French database. Hormone research in paediatrics, 2010;74(2), 121–128. https://doi.org/10.1159/000313377
Grugni, G., Crinò, A., Bosio, L., Corrias, A., Cuttini, M., De Toni, T., Di Battista, E., Franzese, A., Gargantini, L., Greggio, N., Iughetti, L., Livieri, C., Naselli, A., Pagano, C., Pozzan, G., Ragusa, L., Salvatoni, A., Trifirò, G., Beccaria, L., Bellizzi, M., Genetic Obesity Study Group of Italian Society of Pediatric Endocrinology and Diabetology (ISPED). The Italian National Survey for Prader-Willi syndrome: an epidemiologic study. American journal of medical genetics. 2008;Part A, 146A(7), 861–872. https://doi.org/10.1002/ajmg.a.32133
Sinnema, M., Einfeld, S. L., Schrander-Stumpel, C. T., Maaskant, M. A., Boer, H., & Curfs, L. M. Behavioral phenotype in adults with Prader-Willi syndrome. Research in developmental disabilities, 2011;32(2), 604–612. https://doi.org/10.1016/j.ridd.2010.12.014
Khan, M. J., Gerasimidis, K., Edwards, C. A., & Shaikh, M. G. Mechanisms of obesity in Prader-Willi syndrome. Pediatric obesity, 2018;13(1), 3–13. https://doi.org/10.1111/ijpo.12177
Rahman, Q. F. A., Jufri, N. F., & Hamid, A. Hyperphagia in Prader-Willi syndrome with obesity: From development to pharmacological treatment. Intractable & rare diseases research, 2023;12(1), 5–12. https://doi.org/10.5582/irdr.2022.01127
Kweh, F. A., Miller, J. L., Sulsona, C. R., Wasserfall, C., Atkinson, M., Shuster, J. J., Goldstone, A. P., & Driscoll, D. J. Hyperghrelinemia in Prader-Willi syndrome begins in early infancy long before the onset of hyperphagia. American journal of medical genetics. 2015;Part A, 167A(1), 69–79. https://doi.org/10.1002/ajmg.a.36810
Haqq, A. M., Muehlbauer, M. J., Newgard, C. B., Grambow, S., & Freemark, M. The metabolic phenotype of Prader-Willi syndrome (PWS) in childhood: heightened insulin sensitivity relative to body mass index. The Journal of clinical endocrinology and metabolism, 2011;96(1), E225–E232. https://doi.org/10.1210/jc.2010-1733
Rigamonti, A. E., Bini, S., Piscitelli, F., Lauritano, A., Di Marzo, V., Vanetti, C., Agosti, F., De Col, A., Lucchetti, E., Grugni, G., & Sartorio, A. Hedonic eating in Prader-Willi syndrome is associated with blunted PYY secretion. Food & nutrition research, 2017;61(1), 1297553. https://doi.org/10.1080/16546628.2017.1297553
Butler M.G., Manzardo A.M., Heinemann J., Loker C., Loker J. Causes of death in Prader-Willi syndrome: Prader-Willi Syndrome Association (USA) 40-year mortality survey. Genet. Med. 2017;19(6):635–642. https://doi.org/10.1038/gim.2016.178
Nauck, M. A., & Meier, J. J. The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions. The lancet. Diabetes & endocrinology, 2016;4(6), 525–536. https://doi.org/10.1016/S2213-8587(15)00482-9
Yao H, Zhang A, Li D, Wu Y, Wang CZ, Wan JY, Yuan CS. Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis. BMJ. 2024 Jan 29;384:e076410. https://doi.org/10.1136/bmj-2023-076410
Samms, R. J., Coghlan, M. P., & Sloop, K. W. How May GIP Enhance the Therapeutic Efficacy of GLP-1?. Trends in endocrinology and metabolism: TEM, 2020;31(6), 410–421. https://doi.org/10.1016/j.tem.2020.02.006
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., Wilding, J. P., & SCALE Obesity and Prediabetes NN8022-1839 Study Group. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. The New England journal of medicine, 2015;373(1), 11–22. https://doi.org/10.1056/NEJMoa1411892
Tamas T. Varkonyi, Aniko Posa, Noemi Pavo, Imre Pavo. Perspectives on weight control in diabetes – Tirzepatide. Diabetes Research and Clinical Practice. 2023;202, 110770. https://doi.org/10.1016/j.diabres.2023.110770
Baggio, L. L., & Drucker, D. J. Biology of incretins: GLP-1 and GIP. Gastroenterology, 2007;132(6), 2131–2157. https://doi.org/10.1053/j.gastro.2007.03.054
Seufert, J., & Gallwitz, B. The extra-pancreatic effects of GLP-1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems. Diabetes, obesity & metabolism, 2014;16(8), 673–688. https://doi.org/10.1111/dom.12251
Cifuentes, L., Camilleri, M., & Acosta, A. Gastric Sensory and Motor Functions and Energy Intake in Health and Obesity-Therapeutic Implications. Nutrients, 2021;13(4), 1158. https://doi.org/10.3390/nu13041158
Maselli, D. B., & Camilleri, M. Effects of GLP-1 and Its Analogs on Gastric Physiology in Diabetes Mellitus and Obesity. Advances in experimental medicine and biology, 2021;1307, 171–192. https://doi.org/10.1007/5584_2020_496
Garvey, W. T., Frias, J. P., Jastreboff, A. M., le Roux, C. W., Sattar, N., Aizenberg, D., Mao, H., Zhang, S., Ahmad, N. N., Bunck, M. C., Benabbad, I., Zhang, X. M., & SURMOUNT-2 investigators. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023;402(10402), 613–626. https://doi.org/10.1016/S0140-6736(23)01200-X
Wharton, S., Blevins, T., Connery, L., Rosenstock, J., Raha, S., Liu, R., Ma, X., Mather, K. J., Haupt, A., Robins, D., Pratt, E., Kazda, C., Konig, M., & GZGI Investigators. Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. The New England journal of medicine, 2023;389(10), 877–888. https://doi.org/10.1056/NEJMoa2302392
Diene, G., Angulo, M., Hale, P. M., Jepsen, C. H., Hofman, P. L., Hokken-Koelega, A., Ramesh, C., Turan, S., & Tauber, M. Liraglutide for Weight Management in Children and Adolescents With Prader-Willi Syndrome and Obesity. The Journal of clinical endocrinology and metabolism, 2022;108(1), 4–12. https://doi.org/10.1210/clinem/dgac549
Kelly, A. S., Auerbach, P., Barrientos-Perez, M., Gies, I., Hale, P. M., Marcus, C., Mastrandrea, L. D., Prabhu, N., Arslanian, S., & NN8022-4180 Trial Investigators. A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity. The New England journal of medicine, 2020;382(22), 2117–2128. https://doi.org/10.1056/NEJMoa1916038
Salehi, P., Hsu, I., Azen, C. G., Mittelman, S. D., Geffner, M. E., & Jeandron, D. Effects of exenatide on weight and appetite in overweight adolescents and young adults with Prader-Willi syndrome. Pediatric obesity, 2017;12(3), 221–228. https://doi.org/10.1111/ijpo.12131
Danilo Fintini, Graziano Grugni, Claudia Brufani, Sarah Bocchini, Marco Cappa, Antonino Crinò; Use of GLP-1 Receptor Agonists in Prader-Willi Syndrome: Report of Six Cases. Diabetes Care 2014; 37 (4): e76–e77. https://doi.org/10.2337/dc13-2575
Ahmed, S., Naz, A., & K, M. Weight Loss of Over 100 lbs in a Patient of Prader-Willi Syndrome Treated With Glucagon-Like Peptide-1 (GLP-1) Agonists. Cureus, 2023;15(2), e35102. https://doi.org/10.7759/cureus.35102
Kim, Y. M., Lee, Y. J., Kim, S. Y., Cheon, C. K., & Lim, H. H. Successful rapid weight reduction and the use of liraglutide for morbid obesity in adolescent Prader-Willi syndrome. Annals of pediatric endocrinology & metabolism, 2020;25(1), 52–56. https://doi.org/10.6065/apem.2020.25.1.52
Seetho IW, Jones G, Thomson GA, Fernando DJ. Treating diabetes mellitus in Prader‐Willi syndrome with exenatide. Diabetes Res Clin Pract. 2011;92(1):e1‐e2.https://doi.org/10.1016/j.diabres.2010.12.009
Senda M, Ogawa S, Nako K, Okamura M, Sakamoto T, Ito S. The glucagon‐like peptide‐1 analog liraglutide suppresses ghrelin and controls diabetes in a patient with Prader‐Willi syndrome. Endocr J. 2012;59(10):889‐894. https://doi.org/10.1507/endocrj.ej12-0074
Candler T, McGregor D, Narayan K, Moudiotis C, Burren CP. Improvement in glycaemic parameters using SGLT−2 inhibitor and GLP‐1 agonist in combination in an adolescent with diabetes mellitus and Prader‐Willi syndrome: a case report. J Pediatr Endocrinol Metab. 2020;33(7):951‐955. https://doi.org/10.1515/jpem-2019-0389
Crinò, A., Fintini, D., Bocchini, S., & Grugni, G. Obesity management in Prader-Willi syndrome: current perspectives. Diabetes, metabolic syndrome and obesity : targets and therapy, 2018;11, 579–593. https://doi.org/10.2147/DMSO.S141352
Secher, A., Jelsing, J., Baquero, A. F., Hecksher-Sørensen, J., Cowley, M. A., Dalbøge, L. S., Hansen, G., Grove, K. L., Pyke, C., Raun, K., Schäffer, L., Tang-Christensen, M., Verma, S., Witgen, B. M., Vrang, N., & Bjerre Knudsen, L. . The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. The Journal of clinical investigation, 2014;124(10), 4473–4488. https://doi.org/10.1172/JCI75276
Zoicas, F., Droste, M., Mayr, B., Buchfelder, M., & Schöfl, C. GLP-1 analogues as a new treatment option for hypothalamic obesity in adults: report of nine cases. European journal of endocrinology, 2013;168(5), 699–706. https://doi.org/10.1530/EJE-12-0997
Lindgren AC, Barkeling B, Hägg A, Ritzén EM, Marcus C, Rössner S. Eating behavior in Prader‐Willi syndrome, normal weight, and obese control groups. J Pediatr. 2000;137(1):50‐55. https://doi.org/10.1067/mpd.2000.106563
Purtell, L., Sze, L., Loughnan, G., Smith, E., Herzog, H., Sainsbury, A., Steinbeck, K., Campbell, L. V., & Viardot, A. In adults with Prader-Willi syndrome, elevated ghrelin levels are more consistent with hyperphagia than high PYY and GLP-1 levels. Neuropeptides, 2011;45(4), 301–307. https://doi.org/10.1016/j.npep.2011.06.001
Senda Pi-Sunyer X, Astrup A, Fujioka K, et al.. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373(1):11–22. https://doi.org/10.1056/NEJMoa1411892
Crinò A, Fintini D, Bocchini S, Grugni G. Obesity management in Prader-Willi syndrome: current perspectives. Diabetes Metab Syndr Obes. 2018;11:579–593. https://doi.org/10.2147/DMSO.S141352
Irizarry, K. A., Miller, M., Freemark, M., & Haqq, A. M. Prader Willi Syndrome: Genetics, Metabolomics, Hormonal Function, and New Approaches to Therapy. Advances in pediatrics, 2016;63(1), 47–77. https://doi.org/10.1016/j.yapd.2016.04.005
Drucker D. J. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell metabolism, 2018;27(4), 740–756. https://doi.org/10.1016/j.cmet.2018.03.001
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., Steinberg, W. M., Stockner, M., Zinman, B., Bergenstal, R. M., Buse, J. B., LEADER Steering Committee, & LEADER Trial Investigators. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. The New England journal of medicine, 2016;375(4), 311–322. https://doi.org/10.1056/NEJMoa1603827
Van Can, J., Sloth, B., Jensen, C. B., Flint, A., Blaak, E. E., & Saris, W. H. Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults. International journal of obesity, 2014;38(6), 784–793. https://doi.org/10.1038/ijo.2013.162
Reich, N., & Hölscher, C. The neuroprotective effects of glucagon-like peptide 1 in Alzheimer's and Parkinson's disease: An in-depth review. Frontiers in neuroscience, 2022;16, 970925. https://doi.org/10.3389/fnins.2022.970925
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Olga Grelewicz, Adam Juśkiewicz, Elwira Servaas, Mateusz Haber, Paula Kula, Alicja Kotula, Adrianna Czachor, Natalia Kucy
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 144
Number of citations: 0
